Our Team

Elizabeth Reczek, PhD

Elizabeth Reczek, PhD is an Entrepreneur in Residence with Partners Innovation. She is a serial entrepreneur and biotech executive with extensive experience in technological innovation, enterprise strategy development, business development and alliance management, in the context of novel therapeutic, diagnostic and technology programs.  Dr. Reczek received a B.A. in Biochemical Sciences from Harvard University, a Ph.D. in Cancer Biology in the laboratory of Tyler Jacks at the Massachusetts Institute of Technology and completed a four-year post-doctoral fellowship focused on tumor cell signaling pathways at Brigham and Women’s Hospital and Harvard Medical School.  From 2007 to 2015, Dr. Reczek held positions of increasing seniority at Excelimmune, Inc., where was responsible for co-developing the company’s proprietary human antibody discovery platform.  In 2010, she was promoted to Director of Research, where she led the development of the company’s novel recombinant antibody combination expression technology.  She is a co-inventor on a patent describing a novel method for robust and reproducible manufacture of mixtures of recombinant proteins.  In 2013, Dr. Reczek was appointed President and CEO of Excelimmune and served on the Board of Directors.  In early 2015, she negotiated an exclusive license of the company’s core antibody expression technology to Catalent Pharma Solutions.  From 2015 to 2018, Dr Reczek served as CEO of SeqLL, LLC, an innovative Next Gen Sequencing platform company located in Woburn, Massachusetts.